A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Trial Profile

A Randomized, Global, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Once-daily Oral Avatrombopag for the Treatment of Adults With Thrombocytopenia Associated With Liver Disease Prior to an Elective Procedure

Completed
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Avatrombopag (Primary)
  • Indications Thrombocytopenia
  • Focus Registrational; Therapeutic Use
  • Acronyms Adapt I
  • Sponsors Dova Pharmaceuticals; Eisai Inc
  • Most Recent Events

    • 22 Sep 2017 Results published in a Dova Pharmaceuticals media release.
    • 22 Sep 2017 Primary endpoint has been met. (The proportion of participants who require platelet transfusion or rescue therapy for bleed after randomization and up to 7 days after the elective procedure), according to a Dova Pharmaceuticals media release.
    • 22 Sep 2017 According to a Dova Pharmaceuticals media release, based on the data from ADAPT-1 and ADAPT-2 trials the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for avatrombopag, for the treatment of thrombocytopenia in patients with chronic liver disease (CLD) who are scheduled to undergo a procedure.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top